Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease

In brief

The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.

Key facts

Study ID

NCT00913393

Run by

Kyntra Bio

People needed

46

Starts

2009-02-01

Expected to finish

2010-06-01

Last updated by the study team

2019-02-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Tempe, Arizona, United States
• Study site — Buena Park, California, United States
• Study site — Lakewood, California, United States
• Study site — Sacramento, California, United States
• Study site — Walnut Creek, California, United States
• Study site — Whittier, California, United States
• Study site — Atlanta, Georgia, United States
• Study site — Evergreen Park, Illinois, United States
• Study site — Topeka, Kansas, United States
• Study site — Wichita, Kansas, United States
• Study site — Kenner, Louisiana, United States
• Study site — Springfield, Massachusetts, United States
• Study site — Saint Clair Shores, Michigan, United States
• Study site — Lincoln, Nebraska, United States
• Study site — Omaha, Nebraska, United States
• Study site — Berlin, New Jersey, United States
• Study site — Buffalo, New York, United States
• Study site — Flushing, New York, United States
• Study site — New York, New York, United States
• Study site — Greenville, North Carolina, United States
• Study site — Toledo, Ohio, United States
• Study site — Chattanooga, Tennessee, United States
• Study site — Knoxville, Tennessee, United States
• Study site — Dallas, Texas, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.